A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

The drug manufacturer advises keeping Wegovy ... taking a different medication for your condition. Examples of alternatives to Wegovy for weight management include: phentermine (Adipex-P) orlistat ...

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

But these drugs do expire after a few weeks, and microdosing could increase the risk of inadvertently using them after their ...